Stevanato Group publishes third-quarter financial results call transcript
STVN•STVN•STVN•STVN•Stevanato Group reported third-quarter revenue up 8% to €326.1 million and kept its 2026 guidance unchanged at €1.26 billion–€1.28 billion in revenue and €335 million–€345.2 million in adjusted EBITDA. Management expects low-single-digit growth in 2027 as lower GLP-1 volumes from one customer temporarily constrain growth, with more normalized growth expected in 2028.
On its November 3, 2026, third-quarter earnings call, Stevanato Group said revenue rose 8% to €326.1 million. Non-GLP biologics revenue increased more than 30%, offsetting declining GLP-1 sales. Management expects low-single-digit growth in 2027 as lower GLP-1 volumes from one customer temporarily constrain growth; most affected syringe capacity has been backfilled, and more normalized growth is expected in 2028 as broader biologics demand offsets the shortfall. Full-year 2026 guidance remains unchanged at €1.26 billion–€1.28 billion in revenue and €335 million–€345.2 million in adjusted EBITDA.
